SITE MAP 
  HOME  
PHARMA
BIO TECHNOLOGY
MEDICAL TECHNOLOGY
  JOBS  
  FREE SUBSCRIPTION  
  Saturday, August 9, 2008 SEARCH     
 
 
BIO AUSTRALIA
BIO CHINA
BIO INDIA
BIO INDONESIA
BIO JAPAN
BIO KOREA
BIO MALAYSIA
BIO NEW ZEALAND
BIO PHILIPPINES
BIO SINGAPORE
BIO TAIWAN
BIO THAILAND
 
 
Get the latest news on life sciences in your mail box
Name
E-Mail Id
 
 
Advertisement















 
Pharma  Policies  Story
Australia announces changes to PBS for benefit of people

Singapore, Jan 2, 2008: People with pleural mesothelioma, eye conditions, those who want to stop smoking and infants with chest infections will benefit from changes to the Pharmaceutical Benefits Scheme (PBS) that commence from January 1, 2008 in Australia.

The listing of pemetrexed disodium (Alimta) in combination with the drug cisplatin has been extended to include the treatment of pleural mesothelioma. About 300 patients are expected to use pemetrexed disodium each year, at a cost of around $26 million to the PBS and Repatriation Pharmaceutical Benefits Scheme (RPBS) between 2007-08 to 2010-11.

This is an important announcement from the Department of Health and Ageing, government of Australia coming after the tireless campaigning of Mr Bernie Banton, who recently passed away. Mr Bernie Banton was a great Australian hero, and it is due to his efforts that many people will understand the significance of this decision.

Vaxigrip junior is a new form of influenza vaccine suitable for children up to 35 months of age who are at risk of adverse consequences from lower respiratory tract infections (chest infections). This will provide doctors with a more convenient form of influenza vaccine for young children.

From 1 January 2008, optometrists authorized to prescribe certain preparations under state or territory legislation will be able to apply to Medicare Australia for approval to prescribe a limited list of PBS eye medicines. This initiative will cost about $10.7 million over four years. It will improve access to eye treatments for many Australians, particularly concession card holders and people in rural areas.

The addition of varenicline (Champix) will help people who want to stop smoking. This is a new smoking cessation therapy treatment, which assists in reducing the craving and withdrawal symptoms that happen when a person gives up smoking. It is expected around 195,000 people will use varenicline in the first year of listing, at an additional cost to the PBS and RPBS of around $76.3 million over four years to 2010-11.

© BioSpectrum Bureau
  Email this articleComment on this article   Print this article
 
Advertisement





 
   
 
Google
BioSpectrumAsia.com BioSpectrumIndia.com Web

About BioSpectrum | How to Advertise | Jobs at BioSpectrum | Contact Us | Privacy Statement



CyberMedia Network Websites


[Voice&Data]  [PCQuest]  [CIOL]  [Dataquest]  [Living Digital]  [IDC India]
[CIOL Shop]  [DQ Channels]  [The DQweek]  [CyberMedia Dice]  
[CyberMedia Events] [CyberMedia Digital]  [Cyber Astro]  [CyberMedia India]  [Global Services]  [BioSpectrum]

 
Copyrights are reserved for BioSpectrum ; Designed by : Altered Black